2. Treatment with any of the following: i) any investigational agent or study drugs from a previous clinical study within 4 half-lives; ii) any other chemotherapy, immunotherapy, or anticancer agents within 2 weeks; iii) any haematopoietic growth factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF] within 7 days or pegylated G-CSF (pegfilgrastim) or darbepoetin within 14 days of the first dose of study treatment; iv) Prescription or Non-Prescription drugs or other products known to be strong inhibitors/inducers of CYP3A4 that cannot be discontinued prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of the study medication; v) Allogeneic or autologous transplants; v) Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment).